PMC:7299399 / 2686-2877 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":65,"end":69},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma74402"}],"text":"d the development of noninfectious recombinant viral vectors for gene-therapy applications, beginning in 1990.2−4 Efforts were then underway to improve the safety of viral vectors, including "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T52287","span":{"begin":65,"end":69},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"}],"text":"d the development of noninfectious recombinant viral vectors for gene-therapy applications, beginning in 1990.2−4 Efforts were then underway to improve the safety of viral vectors, including "}

{"project":"2_test","denotations":[{"id":"32519842-11642817-158445","span":{"begin":110,"end":111},"obj":"11642817"},{"id":"32519842-32341506-158446","span":{"begin":112,"end":113},"obj":"32341506"}],"text":"d the development of noninfectious recombinant viral vectors for gene-therapy applications, beginning in 1990.2−4 Efforts were then underway to improve the safety of viral vectors, including "}